Literaturliste Chirurgen Magazin + BAO Depesche 2.2020 (Mai 2020)

Hier finden Sie die Literaturlisten zu den Fachbeiträgen in der Rubrik „Medizin“ in Heft 2.2020.

Literaturliste zum Beitrag „Varizenchirurgie – Schaumsklerosierung bei Rezidivvarikose“ von Dr. Jochen Peter (Chirurgen Magazin + BAO Depesche 2.2020, Mai 2020, Seite 48ff.)

  1. National Clinical Guideline Centre. Varicose Veins in the Legs: The Diagnosis and Management of Varicose Veins. London 2013
  2. Peter J, Pourhassan S. Evidence of Foam Sclerotherapy in the Treatment of Recurrent Varicose Veins. Phlebologie 2019; 48 (02): 95–101. doi:10.1055/a-0843-4324
  3. Leitlinie: Sklerosierungsbehandlung der Varikose. (ICD 10: I83.0, I83.1, I83.2, I83.9) AWMF-Leitlinien-Register-Nr.: 037-015 Entwicklungsstufe: S2k; 2018
  4. Noppeney T, Nüllen H. Die Rezidivvarikose — Was ist das? Gefäßchirurgie 2005; 10 (6): 424ff.

Literaturliste zum Beitrag „Aktuelle S3-Leitlinie zur Thromboembolieprophylaxe in der Orthopädie“ von Edith Leisten (Chirurgen Magazin + BAO Depesche 2.2020, Mai 2020, Seite 22ff.)

  1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S.
  2. Cohen AT, Tapson VF, Bergmann J-F, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. The Lancet 2008;371:387–94.
  3. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107:I9-16.
  4. S3-Leitlinie Prophylaxe der venösen Thromboembolie (VTE) 2. komplett überarbeitete Auflage. Stand: 15. Oktober 2015.
  5. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005;131:80–90.
  6. Cafferata HT, Morrison S, Duer C, Depalma RG. Venous thromboembolism in trauma patients: Standardized risk factors. Journal of Vascular Surgery 1998;28:250–9.
  7. Eisele R, Hoellen I, Kinzl L. Drug prophylaxis of deep vein thrombosis in traumatology: is there a benefit of a score in outpatients? Langenbecks Arch Surg 1998;383:481–4.
  8. MM G, FA L, MC P, et al. The Risk Assessment Profile Score Identifies Trauma Patients at Risk for Deep Vein Thrombosis. Surgery 2000;128.
  9. Bohl DD, Maltenfort MG, Huang R, Parvizi J, Lieberman JR, Della Valle CJ. Development and Validation of a Risk Stratification System for Pulmonary Embolism After Elective Primary Total Joint Arthroplasty. J Arthroplasty 2016;31:187–91.
  10. Virchow R. Phlogose und Thrombose im Gefäßsystem.: Gesammelte Abhandlungen zur wissenschaftlichen Medicin. Berlin: Meininger; 1856.
  11. Scottish Intercollegiate Guidelines Network (SIGN) (2002) Prophylaxis of venous thromboembolism. A national clinical guideline (SIGN Pub. No. 62).
  12. Sachdeva A, Dalton M, Amaragiri SV, Lees T. Graduated compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2014:CD001484.
  13. Sajid MS, Desai M, Morris RW, Hamilton G. Knee length versus thigh length graduated compression stockings for prevention of deep vein thrombosis in postoperative surgical patients. Cochrane Database Syst Rev 2012:CD007162.
  14. Loomba RS, Arora RR, Chandrasekar S, Shah PH. Thigh-length versus knee-length compression stockings for deep vein thrombosis prophylaxis in the inpatient setting. Blood Coagul Fibrinolysis 2012;23:168–71.
  15. Ho KM, Tan JA. Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation 2013;128:1003–20.
  16. Collaborative overview of randomised trials of antiplatelet therapy–III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists‘ Collaboration. BMJ 1994;308:235–46.
  17. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e278S-e325S.
  18. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776–86.
  19. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005;106:2710–5.
  20. Junqueira DRG, Perini E, Penholati RRM, Carvalho MG. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 2012:CD007557.
  21. Fachinformation Orgaran (Danaparoid) Stand 2020.
  22. Fachinformation Arixtra (Fondaparinux) Stand 2020.
  23. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833–40.
  24. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160S-198S.
  25. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8S-21S.
  26. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e44S-e88S.
  27. Fachinformation Rivaroxaban (Xarelto 10 mg Filmtabletten) Stand 2019.
  28. Raskob GE, Gallus AS, Pineo GF, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 2012;94:257–64.
  29. Fachinformation Apixaban (Eliquis 2,5 mg Filmtabletten) Stand 2019.
  30. Friedman RJ, Dahl OE, Rosencher N, et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010;126:175–82.
  31. Singer AJ, Wilson S. Reversal Strategies for Newer Oral Anticoagulants. AACN Adv Crit Care 2017;28:322–31.
  32. Fachinformation Argatroban (Argatra1mg/ml Infusionslösung) Stand 2017.
  33. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525–31.
  34. Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002;162:1465–71.
  35. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162–73.
  36. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Canadian Collaborative Group. Chest 1998;114:115S-118S.
  37. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011;105:721–9.
  38. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. The Lancet 2008;372:31–9.
  39. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178–85.
  40. Westrich GH, Haas SB, Mosca P, Peterson M. Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty. J Bone Joint Surg Br 2000;82:795–800.
  41. Kock H-J, Schmit-Neuerburg KP, Hanke J, Rudofsky G. Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg. The Lancet 1995;346:459–61.
  42. Kujath P, Spannagel U, Habscheid W, Schindler G, Weckbach A. Thromboseprophylaxe bei ambulanten Patienten mit Verletzungen der unteren Extremität. Dtsch Med Wochenschr 1992;117:6–10.
  43. Bouyer B, Rudnichi A, Dray-Spira R, Zureik M, Coste J. Thromboembolic risk after lumbar spine surgery: a cohort study on 325 000 French patients. J Thromb Haemost 2018.
  44. Wang T, Yang S-D, Huang W-Z, Liu F-Y, Wang H, Ding W-Y. Factors predicting venous thromboembolism after spine surgery. Medicine (Baltimore) 2016;95:e5776.
  45. Park JH, Lee KE, Yu YM, Park YH, Choi S an. Incidence and Risk Factors for Venous Thromboembolism After Spine Surgery in Korean Patients. World Neurosurg 2019;128:e289-e307.
  46. Kepler CK, McKenzie J, Kreitz T, Vaccaro A. Venous Thromboembolism Prophylaxis in Spine Surgery. J Am Acad Orthop Surg 2018;26:489–500.
  47. Buchanan IA, Lin M, Donoho DA, et al. Venous Thromboembolism After Degenerative Spine Surgery: A Nationwide Readmissions Database Analysis. World Neurosurg 2019;125:e165-e174.
  48. Dattani R, Smith CD, Patel VR. The venous thromboembolic complications of shoulder and elbow surgery: a systematic review. Bone Joint J 2013;95-B:70–4.


Kommentar verfassen

Trage deine Daten unten ein oder klicke ein Icon um dich einzuloggen:

Du kommentierst mit deinem Abmelden /  Ändern )


Du kommentierst mit deinem Facebook-Konto. Abmelden /  Ändern )

Verbinde mit %s